Form 4: BioCardia Director Acquires Stock Options
SEC Form 4 Filing
Director Jim L. Allen acquired stock options in BioCardia, Inc. on October 11, 2024.
Summary
- On October 11, 2024, Jim L. Allen, a director of BioCardia, Inc. (BCDA), acquired stock options.
- The stock options grant the right to buy 829 shares of common stock at an exercise price of $2.65.
- These options vest and become exercisable one year from the grant date, contingent upon continued service.
- Following the transaction, Allen directly owns 3,313 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports a transaction. The acquisition of options by a director is generally viewed as a slightly positive signal, but without further context, it's difficult to assess the overall impact.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/11/2024 | Date of the stock option transaction. |
| 10/11/2034 | Expiration date of the stock options. |
| 10/16/2024 | Date of signature on the Form 4 filing. |
Keywords
stock options, director, BCDA, BioCardia, acquisition, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.